Applied Genetic Technologies’ (AGTC) Overweight Rating Reiterated at Cantor Fitzgerald

Applied Genetic Technologies (NASDAQ:AGTC – Get Rating)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Tuesday, Zacks.com reports.

AGTC has been the subject of a number of other research reports. Stifel Nicolaus reiterated a “buy” rating and set a $10.00 price target on shares of Applied Genetic Technologies in a report on Thursday, April 14th. Roth Capital reiterated a “buy” rating on shares of Applied Genetic Technologies in a research note on Tuesday, February 8th. Chardan Capital restated a “buy” rating on shares of Applied Genetic Technologies in a research note on Monday, April 11th. Finally, StockNews.com began coverage on shares of Applied Genetic Technologies in a research report on Thursday, March 31st. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

Shares of AGTC opened at $0.84 on Tuesday. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $1.13 and its 200 day simple moving average is $1.76. Applied Genetic Technologies has a 1-year low of $0.58 and a 1-year high of $4.65. The company has a market cap of $35.95 million, a price-to-earnings ratio of -0.55 and a beta of 1.65.

Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) last released its quarterly earnings data on Monday, February 14th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same period in the prior year, the business posted ($0.60) EPS. As a group, research analysts forecast that Applied Genetic Technologies will post -1.63 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP boosted its holdings in Applied Genetic Technologies by 366.5% in the 3rd quarter. GSA Capital Partners LLP now owns 583,510 shares of the biotechnology company’s stock valued at $1,756,000 after purchasing an additional 458,420 shares during the period. Millennium Management LLC boosted its stake in shares of Applied Genetic Technologies by 26.0% in the fourth quarter. Millennium Management LLC now owns 1,533,193 shares of the biotechnology company’s stock valued at $2,913,000 after buying an additional 316,276 shares during the period. Vanguard Group Inc. grew its position in Applied Genetic Technologies by 14.4% during the first quarter. Vanguard Group Inc. now owns 1,981,565 shares of the biotechnology company’s stock worth $2,120,000 after buying an additional 248,819 shares in the last quarter. Portolan Capital Management LLC increased its stake in Applied Genetic Technologies by 18.0% during the 1st quarter. Portolan Capital Management LLC now owns 1,605,599 shares of the biotechnology company’s stock worth $1,718,000 after acquiring an additional 244,895 shares during the period. Finally, Two Sigma Advisers LP raised its holdings in Applied Genetic Technologies by 152.4% in the 3rd quarter. Two Sigma Advisers LP now owns 327,129 shares of the biotechnology company’s stock valued at $985,000 after acquiring an additional 197,500 shares in the last quarter. 38.03% of the stock is currently owned by hedge funds and other institutional investors.

Applied Genetic Technologies Company Profile (Get Rating)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials.

Further Reading